Navigation Links
Intellect Neurosciences Issues Letter to Shareholders
Date:10/14/2011

NEW YORK, Oct. 14, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,

I would like to take this opportunity to update you about pertinent corporate and industry developments contemporaneous with the current filing of our quarterly financial statements with the SEC.

Of special note is our recent transaction with ViroPharma Inc., which was announced September 30, 2011. Intellect granted an exclusive license to ViroPharma regarding certain of Intellect's licensed patents and patent applications related to Intellect's clinical stage drug candidate, OX1, an extremely potent antioxidant molecule that has been demonstrated to protect nerve cells in the brain from highly oxidizing neurotoxins. ViroPharma plans to develop and commercialize OX1 as a treatment of Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.  Under the terms of the license agreement, Intellect received an upfront payment of $6.5 million, and will receive up to an additional $120 million based on defined events and a tiered royalty of up to a maximum of low double digits based on annual net sales.  In exchange, Intellect transferred to ViroPharma all of Intellect's intellectual property rights, data and know-how, assembled over several years related to its OX1 research and development program.  NYU Medical School and University of South Alabama, which own certain patents in relation to OX1, are entitled to a portion of the revenues received by Intellect from ViroPharma pursuant to an exclusive license agreement between Intellect Neurosciences and those universities.

I am particularly gratified by the interest shown i
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
4. PILMA Vows to Redouble Support for Increased Protections Against Intellectual Property Theft
5. Dehaier Strengthens Intellectual Property Portfolio
6. NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve OClock Noon
7. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
8. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
9. NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve OClock Noon
10. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
11. As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, 2014 ... than traditional cigarettes, new research finds. Even though ... thousands of ex-smokers said they have fewer cravings and are ... to smoke, researchers reported. "The pattern was ... use than for tobacco use," said lead researcher Jonathan Foulds, ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage Rock ... the Doors International Ballroom at the Hilton Hotel in ... only time that Morrison's mother would see her son ... According to Hawley, “This would be the Doors only ... Roller Rink earlier that year and would return to ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Theme ... announced a new intro plugin for Final Cut Pro ... pictures, videos, logos, and more with absolute ease.” Said ... our users the tools needed to easily animate their ... Final Cut Pro X users to animate pictures, videos, ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and ... Fairfax, VA., today announced it has been recognized by ... which ranks the fastest growing government contracting small businesses by ... , This is the first year that Concept Plus, LLC., ... with a 95.92% compound annual growth rate. “For Concept Plus ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2
... a better choice, researchers say , , TUESDAY, Sept. 11 (HealthDay ... of diabetics to control blood sugar, greatly increases their risk ... drug does not up users, overall risk of death, however, ... benefits has shifted, and this needs to be factored into ...
... Provide New Levels of Protection, PITTSBURGH, Sept. ... leading developer of sophisticated safety equipment, today,announced that ... certified as meeting new rigorous performance requirements adopted,by ... M7 Air,Mask is the first device of its ...
... (Nasdaq: EMITF ) ("EMI") announced today that it had ... offering,of Series E Notes and Series F Notes in the ... be conducted in two separate tenders based on the,annual interest ... The Offering,Prospectus provides that the maximum interest rate of the ...
... 11, 2007 - A history of maternal epilepsy and ... later in life, says a new study published in ... Bergen and Norwegian Institute of Public Health, Bergen, Norway, ... with and without epilepsy, and found a correlation between ...
... Aviv Universitys Sackler School of Medicine is, quite simply, a ... of a small number of surgeons in the world who ... has developed a novel laser device that promises to revolutionize ... now, is expected to give most practicing eye surgeons the ...
... ... troops, PHOENIX, Sept. ... returning Guard members, TriWest Healthcare,Alliance, the Department of Defense,s TRICARE contractor in ... first Combat,Stress Video Conference. The conference, being held from 2 to 5 ...
Cached Medicine News:Health News:Diabetes Drug Avandia Boosts Heart Risks: Study 2Health News:Diabetes Drug Avandia Boosts Heart Risks: Study 3Health News:MSA's Next-Generation Breathing Apparatus for Firefighters First to Receive Full NFPA Approval 2Health News:MSA's Next-Generation Breathing Apparatus for Firefighters First to Receive Full NFPA Approval 3Health News:Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel 2Health News:Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel 3Health News:Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel 4Health News:Glaucoma surgery in the blink of an eye 2Health News:TriWest and Montana VA Launch PTSD Video Conference to Reach Rural Health Care Providers 2
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: